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A decade of adverse drug events in
Portuguese hospitals: space-time clustering
and spatial variation in temporal trends
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Abstract
Background: The aim of this study is to identify the distribution by municipalities of adverse drug events (ADE) in
Portugal, including adverse drug reactions (ADR) and accidental poisoning by drugs (AP), on municipality/years ADE
rate clustering. Also we identify areas with different trends in time.
Methods: We used a national dataset of public hospital discharges in Continental Portugal from 2004 to 2013.
Events were identified based on codes: from E930 to E949.9 (ADR) and from E850 to E858.9 (AP). Space-time
clustering and spatial variation in temporal trends methods were applied in three different time-periods: globally,
by year and grouped in 2 classes (periods of 5 years).
Results: A total of 9,320,076 patients were discharged within this period, with 133,688 patients (1.46%) having at
least one ADE, 4% of them related with AP. Critical space-time identified clusters (p < 0.001) were the municipalities
from Lisbon metropolitan area and Centro region area. The global rate increased at a 7.8% mean annual
percentage change, with high space-time heterogeneity and variation in time trends clusters (p < 0.001). For whole
period, 2004–2013, all clusters presented increasing trends. However when analyzed by period of 5 years we
identified two clusters with decreasing trends in time in 2004–2008.
Conclusion: The impact of ADE is huge, with widely variations within country and in time, and represents an
increasing challenge. Future research using individual and contextual risk factors are urgently needed to understand
this spatiotemporal variability in order to promote local tailored and updated actions of prevention.
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Background
The use of the drugs, in addition to the benefit brought,
may include some risks, is that at some point the patient
may suffer an iatrogenic process, which can cause injuries
with different levels of severity, potentially requiring
patient hospitalization [1].
In the last decade organizational structures of pharma-
covigilance have been continuously improved, with a
closer supervision of the drugs over a long period of
time including after the approval of commercialization.
Pharmacovigilance is a key element of effective activity
with the drugs, the medical practice and public health
programs [2].
Studies have estimated a varied percentage of incidences
of adverse events related with the drugs leading to
hospitalization ranges from 2.4% to 6.5% of all hospitaliza-
tions in Western European countries [3–6]. Regarding the
elderly, this percentage is higher, ranging between 3.4% and
16.6% [3, 4]. The percentage of patients with one or more
adverse drug events during hospitalization varies between
1.8% and 19.2%, resulting in increased hospitalization time
and thus the costs [7, 8]. In Lagnaoui et al., the incidence
rate for in-hospital adverse drug reactions was 10.1 per
1000 patient-days [9]. Geographic epidemiology studies can
help to detect regions with rising incidences of adverse drug
events and differences in drug utilization [10].
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In literature review of Patel and Peter in 2002 regard-
ing the visits to the emergency department, it was
estimated that 28% of these were due to adverse drug
events, of which 24% required hospitalization, and
70–80% were avoidable adverse events [11, 12].
Geographical information systems and spatial analysis
provide important tools for disease control, where the
place can be considered as proxy for the interaction be-
tween genetic factors, lifestyle and environment [13, 14].
Spatial autocorrelation statistics provide useful informa-
tion about the spatial arrangement of data in a map and
the correlation or dependency rates for geographically
close areas with application in several sciences such as
criminology, ecology, public health [15–18]. Spatial scan
statistics [15] is one of the most used methods, identify-
ing potential clusters by drawing circles of different sizes
over the area of study and compare the risk of disease
inside and outside of each circle [18]. Advances in meth-
odology of spatial epidemiology create opportunities for
researcher to improve reporting of disease at national or
regional scale, even in small areas, although this studies
are susceptible to confusing results related with small
numbers [19]. Two methodological methods were ap-
plied in this study, space–time clustering and spatial
variation in temporal trends, enabling the identification
of areas where major problems and areas with temporal
trends different from the rest of the country. The use of
these two methods is a very powerful tool to improve
knowledge in public health.
The study objectives are to identify spatiotemporal
municipality-years incidence rate high clusters of adverse
drug events (ADE) based on the hospital discharges data-
set in Portugal from 2004 to 2013 and find spatial clusters
of incidence with different trends in the same period. This
study aims to contribute to public health management fo-
cused on adverse drug events and as we know, is the first
nationwide study using this methodology.
Methods
Using the Portuguese hospital inpatient discharges data-
set from 2004 to 2013 a retrospective observational na-
tionwide study was using the International Classification
of Diseases (ICD-9). In the analysis were included
patients with ADE by geographical area being the
geographical unit “municipality” - in mainland Portugal
(n = 278).
The dataset has patients’ anonymized information and
the variables used were: year, sex, age, length of stay,
discharge status (home, transferred, dead, and so on),
hospital’s region (of five Regional Health Administrations
– RHA) and external causes (E codes). All day episodes
were excluded from the analyses. ADE were defined as
injuries resulting from the use of prescription and over-
the-counter medications for medical intervention, which
includes adverse drug reactions and medication error and
excludes administration of the wrong medication,
intentional overdoses or use of illicit substances, in agree-
ment with the literature [20–24].
Based on literature, the following E codes were used
from ICD-9: E930 to E949.9 of ADR and E codes from
E850 to E858.9 (specifically for AP) [24–26].
The unit of analysis is annual rate of adverse drug events
per 10 000 hospitalizations between 2004 and 2013.
Patient admitted multiple times in hospital are accounted
for each time separately. For the rate’s numerator were
considered annual discharges with adverse drug events by
patients’ municipalities. The denominator were taken all
annual discharges by year in ten-year’ time period.
As a first approach a descriptive analysis was performed,
followed by two clustering methods. First we use the clas-
sical space-time clustering to identify high incidence areas,
followed by the analysis of the spatial variation in tem-
poral trends. For this, a retrospective space-time analysis
using a Poisson distribution for identification of the ele-
vated disease risk within a cluster, using SaTScan Software
[27], was done. Cluster analysis can detect and identify
geographic areas that have significant differences in risk,
regardless of their size. SaTScan software, based in
Kulldorff ’s statistical methodology, uses the spatial scan
and is routinely used in public health [17, 27–29].
A first clustering analysis was conducted for the whole
period from 2004 up to 2013. After, based on the obtained
results, this period was split in two smaller periods,
2004–2008 and 2009–2013, to evaluate the consistency of
clusters found and respective trends. Data were analyzed
using a statistical significance level of 5%.
The results were mapped using the Epi Info
software [30].
Results
Table 1 illustrates the distribution of patient discharges
(all, ADE and subgroups), globally and by year. The ana-
lysis shows a slight increase in the number of all ADE in
general, with an increase in ADR since 2005, although
the AP are more stable in evolution in the period
studied. An increase of 70% for ADE was observed
during the period, with 11,007 events in 2004 and reach-
ing 18,750 in 2013.
Descriptive statistics are presented in Table 2, by year
and globally, and also identifying the municipalities with
highest ADE rates.
The municipality with the highest ADE rate changed
every year. In most of the years (8 out of 10) the minimum
rate was zero, with a proportion of municipalities with rate
zero between 0.3 and 4.6%. Moreover the higher rates of
ADE are concentrated in two country regions, Alentejo (58
municipalities) and Centro (78 municipalities), being these
two profiles associated with small discharges numbers.
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Figure 1 presents the space-time clusters of higher
rates of ADE in Portugal, in three periods: 2004–2013,
2004–2008 and 2009–2013.
Table 3 presents the characteristics of critical areas
(identified clusters), considering the overall period
(2004–2013) and the two half periods (2004–2008;
2009–2013). This split was based on 2004–2013 results.
Table 4 shows the result for the spatial variation in
temporal trends of ADE rates for the three time periods
being studied (2004–2013; 2004–2008; 2009–2013).
Additionally Figs. 2 present the incidence rate trends
and spatial distribution of the identified clusters for the
same three studied time-periods.
Discussion
To our knowledge this is the first space-time study aiming
to understand the phenomena of adverse drug events at
national level in Portugal. This analysis contributes with
two important results: 1) the variability in space and time
within the country and 2) increasing rate of ADE for the
whole time period with all significant clusters increasing
above the national mean.
In 2004–2013 period, we have identified an increase
proportion of ADE in all discharges (1,1% in 2004 and
2,1% in 2013). Also in this period a slight increase in the
number of overall hospitalizations was observed. Many of
the side effects are associated with specific factors related
with the patient and/or with the drug. The evolution of
the treatments alternatives being used (with more and
stronger drugs available on the market) and increase in
average life expectancy can be considered as principal rea-
sons for ADE. Other factors that contribute to adverse re-
actions are related with the accuracy of the prescribing,
dispensing and administration of the drugs [31]. Risk fac-
tors related with patients include older age, female sex,
drugs in therapy and the number of associated comorbidi-
ties [32–34]. Determining the incidence of adverse drug
reactions may be difficult, because frequently drugs are
not recognized as the cause of symptoms or diseases [35].
Not all studies accurately disentangle ADE leading to
hospitalization and hospital-acquired ADE what becomes
a confounder in the results obtained.
When space-time clustering was applied to the whole
period 2004–2013, the municipalities from Lisbon metro-
politan area (clusters 1) were identified as critical in the
2009–2013 period and Centro region area (cluster 2) was
identified as critical in time frame 2010–2013. Using the
same analysis for the two sub-periods, with a cut-off point
in 2008/2009, similar critical areas were identified in the
2004–2008 period for the years 2006–2007 in the Lisbon
metropolitan area (cluster 3) and in years 2007–2008 for
the Centro Region (cluster 4). For the second period
Table 1 Distribution of ADR & AP by year and globally
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% ADE in all
discharges
1.1% 1.1% 1.3% 1.3% 1.3% 1.4% 1.5% 1.7% 1.9% 2.1% 1.5%
Table 2 Description of ADE rates in the 278 municipalities of continental Portugal, globally and yearly
Year Maximum (Municipality, No. of cases) Minimum (No. of Municitality, %) Mean Median S.D.
2004 227.9 (Lisboa,1402) 0 (4; 1.4) 92.9 89.1 52.1
2005 285.7 (Mertola, 2)a 0 (6; 2.2) 95.4 87.4 56.9
2006 355.8 (Lagoa, 10) 0 (10; 3.5) 106.9 99.5 65.3
2007 735.2 (Castro Verde, 5)a 0 (13; 4.6) 108.5 101.1 88.7
2008 510.2 (Vidigueira, 5)a 0 (5; 1.8) 111.2 104.4 67.7
2009 592.5 (Ferreira do Alentejo, 8)a 0 (5; 1.8) 131.3 122 70.9
2010 349.1 (Sardoal, 14)b 9.2 (1; 0.3) 136.5 130.5 60.4
2011 353.9 (Penedono, 8) 18.8 (1; 0.3) 147.1 145.3 66.3
2012 429.7 (Vouzela, 41)b 0 (1; 0.3) 168.5 162.1 66.1
2013 501.6 (Penalva do Castelo, 45)b 0 (1; 0.3) 209 198.2 83.6
GLOBAL 268.2 (Oeiras, 3791) 31.1 (1; 0.3) 127.5 126.2 42.9
aMunicipalities from Alentejo Region; bMunicipalities from Centro Region
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(2009–2013), we further identified three clusters besides
the ones already known. These three clusters are located
in the Oporto metropolitan area, Algarve Region and
Centro Region. All the clusters in this period are consid-
ered as critical for the years 2012 and 2013.
Previous studies have shown the rate of ADR in hospital
inpatients ranging from 0.8% to 26.1% [7–9, 36, 37].
Studies using administrative datasets have shown rates of
ADR between 0.8% and 1.8% in Europe [26, 37, 38]. The
differences in the results observed can be due to differ-
ences in the accuracy of data reporting in the datasets
used or to the definition of the ADR.
A large number of studies points towards an in-
creasing trend of ADR over time [38–40]. In our
study the spatial variation in temporal trends of ADE
the mean annual percentage change in the rate was
7.8% for the period 2004–2013, 3.7% for 2004–2008
and 11.2% for 2009–2013. During 2004–2013 six sig-
nificant clusters were identified and all of them
present increasing trends for the ADE’ rate. Clusters
II, IV and VI showed a slower increase in the mean
annual trend (3.8%, 4.8% and 1.4%) when compared
against the country global mean annual trend (7.8%).
The mean annual trend for the remaining clusters
increased faster than the country mean.
In the period 2004–2008 seven clusters with signifi-
cant variations were identified. Only two clusters with
decreasing trends were found, clusters IX and XI with
rates of −2.9% and −2.2%, respectively. In this period
cluster VIII showed an accelerated increase with a rate
2004-2013 2004-2008 2009-2013
Fig. 1 Space-time clusters of higher rate of ADE cases in three periods
Table 3 Space-time clusters with higher rate of ADE in three time periods (2004–2013, 2004–2008 and 2099–2013) (p < 0.001)
Time period Clusters No. Of municipalities Time frame Observed/expected ratio
2004–2013 A 48 2010–2013 1.36
B 5 2009–2013 1.75
2004–2008 A 8 2007–2008 1.43
B 6 2006–2007 1.75
2009–2013 A 39 2012–2013 1.33
B 5 2012–2013 1.61
C 5 2012–2013 1.62
D 4 2012–2013 1.60
E 8 2012–2013 1.58
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Table 4 Space clusters of temporal trends of ADE incidence rate found in 2004–2013, 2004–2008 and 2009–2013. Positive and
negative percentages correspond to increasing or decreasing trends, respectively








ADE rate x 10¯4 in
period a
ADE rate x 10¯4 in
period b
2004–2013 I 16403 (44) 14,8 65.8 204.6
(7,83%) II 36146 (8) 3,8 184.6 253.7
III 12883 (38) 11.4 91.3 202.5
IV 13528 (40) 4.8 117.3 177.9
V 3841 (9) 12.4 103.4 287.5
VI 1126 (8) 1.4 79.8 142.1
2004–2008 VII 2997 (26) 17.1 95.8 165.1
(3,70%) VIII 335 (2) 40.1 46.1 164.1
IX 5135 (8) −2.9 122.1 115.5
X 2699 (3) 12.9 108.2 158
XI 4216 (30) −2.2 114.7 103.2
XII 1157 (10) 15.9 62.5 101.4
XIII 584 (2) 19.6 87 150.7
2009–2013 XIV 17598 (15) 4.5 190.7 226.8
(11.20%) XV 12837 (44) 19.5 103.4 204.6
XVI 7651 (62) 5.9 127.5 169.8
XVII 1692 (10) 21.6 109.4 266.5
Values in bold identified areas where trends were higher than global trends (for each a-b period)

















Fig. 2 Spatial variation in temporal trends of ADE incidence rate in three periods
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reaching 40.1%, with an increase in the rate of ADE
from 46 cases to 164 cases/10 000 inpatients.
In the period 2009–2013 four clusters with significant in-
creases were identified. Clusters XIV and XVI showed a
slower increase in their trend when compared with the
country mean. In this period Cluster XVII showed an in-
crease in the mean percentage rate (21.6%) that was twice
the observed in the country mean.
The mean annual change in rate for the period 2004 to
2013 was 7.8%, although in 2009–2013 an accelerate
increase in rate was detected. Globally all clusters present
increasing trends, however cluster VI, the smaller one in
this period including eight municipalities with 10 112 dis-
charges, shows an irregular trend in 2009. A very acceler-
ate trend was identified for cluster V, belonging to the
South region of the country, that was not identified as
critical the half periods.
Decreasing trends are only observable in the period
2004–2008, with cluster IX including Oporto
metropolitan area and cluster XI placed in region Centro
and Alentejo. Comparing with the increasing rate in this
period, reaching in cluster VIII an annual increase per-
centage of 40.1%, the decreasing rate are very small with a
percentage rate only −2.9% in cluster IX and −2.2% in
cluster XI. Clusters with high increasing trends comprised
a small number of municipalities. Such clusters should be
analyzed more closely, as their trend may be explained by
the variation of small numbers or administrative issues.
We must also mention that clusters with decreasing
trends (IX and XI) are bigger, as per the number of pa-
tients discharged, when compared with the clusters with
increasing trends (VII, VIII, X, XII and XIII) in same
period. Critical areas, identified through space-time clus-
tering were partially consistent with the municipalities
with the maximum rate obtained in the descriptive ap-
proach. Space-time clustering analysis is preferred for
identified critical areas, even in small numbers although a
careful interpretation of this results and future studies
must be considered [41].
The number of ADE has increased in the last decade in
Portugal, with the subgroup of AP being more stable in
time than ADR. High variability across country was
observed and the method applied to this study, a combin-
ation between space-time clustering and spatial variation
in temporal trends, allow the identification of the areas
with high risk and with temporal trend different from the
rest of the country.
The increase in the frequency of ADE was expected
considering several factors that can contribute for ADE
(new drugs, population ageing, multiple drugs in therapy,
comorbidities etc.) but the variations must be understand
[32–34, 42]. Results are consistent with other studies
using administrative hospital datasets which report in-
creasing trends of ADE related hospitalizations in
England, Germany and Sweden. Current efforts worldwide
are now being developed to reduce morbidity and mortal-
ity related to drugs and the application of this method-
ology provides better knowledge to set geographic
priorities within the country pharmacovigilance system.
In this analysis we assumed homogeneity in the codifi-
cation and in the notification rate in space and time. If
this situation does not occur biases can affect the study
results.
Conclusion
The mean annual percentage change in ADE rate in the
period 2004–2013 was 7.8%, with all clusters in an
increase trend. In the first half period 2004–2008, the
increase was slighter lower (3.7%) but in the period
2009–2013 we observed an accelerate increase reaching
11.2%. Identified high incidence areas weren’t overlap
with trends results, but joint analysis of these results
raises very promising prospects for the design of future
interventions to control this challenging problem. The
impact of ADE is huge, with widely variations within
country, and presents an increasing pattern. Future re-
search using individual (comorbidities, concomitant
medication, life style or genetic predisposition) and con-
textual risk factors (regional variability related with
health services) can be helpful to explain this spatiotem-
poral variability in order to promote local tailored and
updated actions of prevention.
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